Table 4 Relation between response to treatment and investigated markers
From: Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
Response | IDH1 mutant (n = 15) | MGMT methylated (≥ 66%) (n = 30) |
|---|---|---|
Complete response (CR) (n = 15) | 12 (80%) | 12 (40%) |
Partial response (PR) (n = 7) | 3 (20%) | 8 (26.7%) |
Stable disease (SD) (n = 8) | 0 (0%) | 5(16.7%) |
Progressed disease (PD) (n = 28) | 0 (0%) | 5 (16.7%) |
|  | X2 = 35, P < 0.0001 | X2 = 26, P < 0.0001 |